Entero Therapeutics (FWBI) Stock Forecast, Price Target & Predictions
FWBI Stock Forecast
Entero Therapeutics stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
FWBI Analyst Ratings
According to 1 Wall Street analysts, Entero Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for FWBI stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 26, 2022 | Roth Capital | Buy | Buy | Hold |
Entero Therapeutics's last stock rating was published by Roth Capital on May 26, 2022. The company gave FWBI a "Buy" rating, the same as its previous rate.
Entero Therapeutics Financial Forecast
Entero Therapeutics Revenue Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Oct 22 | Mar 22 | |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $-4.43K | $-7.00K |
| High Forecast | - | - | - | - | $-4.43K | $-7.00K |
| Low Forecast | - | - | - | - | $-4.43K | $-7.00K |
| # Analysts | - | - | - | 1 | - | - |
| Surprise % | - | - | - | - | - | - |
Entero Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. FWBI's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Entero Therapeutics EBITDA Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Oct 22 | Mar 22 | |
|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 1 | - | - |
| EBITDA | - | - | - | - | - | $-9.61M |
| Avg Forecast | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - |
undefined analysts predict FWBI's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Entero Therapeutics's previous annual EBITDA (undefined) of $NaN.
Entero Therapeutics Net Income Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Oct 22 | Mar 22 | |
|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 1 | - | - |
| Net Income | - | - | - | - | - | $-9.87M |
| Avg Forecast | $-10.16M | $-11.61M | $-14.44M | $-31.56M | $-6.12B | $-21.64B |
| High Forecast | $-10.16M | $-11.61M | $-14.44M | $-31.56M | $-6.12B | $-21.64B |
| Low Forecast | $-10.16M | $-11.61M | $-14.44M | $-31.56M | $-6.12B | $-21.64B |
| Surprise % | - | - | - | - | - | 0.00% |
Entero Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. FWBI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Entero Therapeutics SG&A Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Oct 22 | Mar 22 | |
|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 1 | - | - |
| SG&A | - | - | - | - | - | $4.41M |
| Avg Forecast | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - |
Entero Therapeutics's average Quarter SG&A projection for Oct 22 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to FWBI last annual SG&A of $4.41M (Mar 22).
Entero Therapeutics EPS Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Oct 22 | Mar 22 | |
|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 1 | - | - |
| EPS | - | - | - | - | - | $-133.36 |
| Avg Forecast | $-0.70 | $-0.80 | $-0.99 | $-2.17 | $-421.40 | $-1.49K |
| High Forecast | $-0.70 | $-0.80 | $-0.99 | $-2.17 | $-421.40 | $-1.49K |
| Low Forecast | $-0.70 | $-0.80 | $-0.99 | $-2.17 | $-421.40 | $-1.49K |
| Surprise % | - | - | - | - | - | 0.09% |
According to undefined Wall Street analysts, Entero Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to FWBI previous annual EPS of $NaN (undefined).
Entero Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EFTR | eFFECTOR Therapeutics | $0.04 | $5.50 | 13650.00% | Buy |
| FWBI | Entero Therapeutics | $2.96 | $270.00 | 9021.62% | Buy |
| BWV | Onconetix | $0.18 | $4.00 | 2122.22% | Buy |
| XFOR | X4 Pharmaceuticals | $0.66 | $3.67 | 456.06% | Buy |
| IMMX | Immix Biopharma | $1.85 | $7.00 | 278.38% | Buy |
| DRMA | Dermata Therapeutics | $2.32 | $6.00 | 158.62% | Buy |
| ZURA | Zura Bio | $3.59 | $5.00 | 39.28% | Buy |
FWBI Forecast FAQ
Is Entero Therapeutics a good buy?
Yes, according to 1 Wall Street analysts, Entero Therapeutics (FWBI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of FWBI's total ratings.
What are Entero Therapeutics's analysts' financial forecasts?
FWBI's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-67.769M (high $-67.769M, low $-67.769M), average SG&A $0 (high $0, low $0), and average EPS is $-4.67 (high $-4.67, low $-4.67).